See more : AVRA Medical Robotics, Inc. (AVMR) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Mears Group plc (MER.L) Income Statement Analysis – Financial Results
- Montage Technology Co., Ltd. (688008.SS) Income Statement Analysis – Financial Results
- Global Power Synergy Public Company Limited (GPSC-R.BK) Income Statement Analysis – Financial Results
- Great Lakes Dredge & Dock Corporation (GLDD) Income Statement Analysis – Financial Results
- Nova Ltd. (NVMI.TA) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences reports increased revenues, profits for Q3
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) reported robust financial performance for the third quarter ending September 30, 2024. The company achieved a 101% year-over-year revenue increase to $6.5 million, surpassing management's guidance.
BioHarvest Sciences launches VINIA SuperFood Teas
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has expanded its product offerings with the launch of VINIA SuperFood Functional Teas, marking a strategic move into the $3.3 billion North American functional tea market. The new line features four premium blends: Black Tea, Green...
BioHarvest shares rise in Nasdaq debut
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) began trading on the Nasdaq Global Market on Tuesday under the ticker symbol "BHST." Shares of the company gained nearly 5% in early morning trading, reaching US$6 just after the opening bell.
BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market
Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented...
BioHarvest Sciences Announces Record Preliminary Third Quarter 2024 Financial Results
Management Guides Fourth Quarter Revenues to Grow to at Least $7.2 Million USD; Reaffirms Goal to Complete Nasdaq Uplisting by Year-End Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 23, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest"...
BioHarvest Sciences to Participate in LD Micro Main Event XVII Conference on October 30, 2024
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 16, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that management has been invited to attend...
BioHarvest Sciences Reports Director's Ongoing Key Role Following Resignation from Board
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 20, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), announces the resignation of David Ryan as a director of the Company. Mr. Ryan will remain a key...
BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on September 24-25, 2024
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 12, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that it has been invited to...
BioHarvest Sciences to Present at H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 4, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced it will participate in the H.C. Wainwright...
BioHarvest Sciences Reports Record Second Quarter 2024 Financial Results
Q2 2024 Revenue Increased 119% Year-over-Year to Over $6.0 Million, Exceeding Management Guidance Management Expects Third Quarter 2024 Revenues of at Least $6.5 Million, with a Gross Profit Margin of 52%+ Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August...
Source: https://incomestatements.info
Category: Stock Reports